Remus Pharmaceuticals Limited — Others, 09-01-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Remus Pharmaceuticals has confirmed the completion of securities dematerialization for the quarter ended December 31, 2024. The company received a certificate from MUFG Intime India Pvt. Ltd., detailing the acceptance and processing of securities, ensuring they are listed on relevant stock exchanges. This update reflects efficient management of shares and compliance with dematerialization requirements. Investors may view this as a positive signal of operational effectiveness and adherence to governance standards, potentially enhancing stakeholder confidence in the company's processes and stability.